NDA 021392 · Bausch
Cardizem La
Diltiazem Hydrochloride · Oral
Last checked: Nov 20, 2026Latest source record: Apr 16, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2003
Feb 6, 2003
Approved uses
2
Original approval plus efficacy supplements
Registered trials
127
21 Phase 3, 6 recruiting
FAERS reports
12,237
10,144 serious, 2,820 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 11, 2025.
CARDIZEM LA is a nondihydropyridine calcium channel blocker indicated for: • treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It can be used alone or in combination with other antihypertensives. ( 1.1 ) • improving exercise tolerance in patients with chronic stable angina. ( 1.2 ) 1.1 Hypertension CARDIZEM ® LA is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome...
Mechanism: The therapeutic effects of diltiazem are believed to be related to its ability to inhibit the cellular influx of calcium ions during membrane depolarization of cardiac and vascular smooth muscle. Hypertension: Diltiazem produces its antihypertensive effect primarily by relaxation of vascular smooth muscle and the resultant decrease in peripheral vascular resistance. The magnitude of blood pressure reduction is related to the degree of hypertension; thus hypertensive individuals experience an antihypertensive effect, whereas there is only a modest fall in blood pressure in normotensives....
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 2, 2004 Supplement 2 · Efficacy LabelReviewLetter
- Feb 6, 2003 Original approval · Type 3 - New Dosage Form LabelReview
6 products under this application
- CARDIZEM LA · DILTIAZEM HYDROCHLORIDE 120MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
- CARDIZEM LA · DILTIAZEM HYDROCHLORIDE 420MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
- CARDIZEM LA · DILTIAZEM HYDROCHLORIDE 300MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
- CARDIZEM LA · DILTIAZEM HYDROCHLORIDE 180MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
- CARDIZEM LA · DILTIAZEM HYDROCHLORIDE 360MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
- CARDIZEM LA · DILTIAZEM HYDROCHLORIDE 240MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Diltiazem" as an intervention, any sponsor and status, largest first.
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000620 · 10,251 participants · Start Sep 1999 · Primary completion Jun 2009
Drug: Anti-hyperglycemic Agents; Anti-hypertensive Agents and 1 more · For: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia and 4 more
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
- Coronavirus (COVID-19) ACEi/ARB InvestigationPivotal-lookingSuspended
National University of Ireland, Galway, IrelandAcademic, hospital or other
NCT04330300 · 2,414 participants (planned) · Start Apr 30, 2020 · Primary completion Jul 31, 2021
Drug: Thiazide or Thiazide-like diuretics; Calcium Channel Blockers and 2 more · For: Hypertension; COVID-19
Sites: Galway, Ireland
- Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation TrialPivotal-lookingCompleted
Mayo ClinicAcademic, hospital or other
NCT00911508 · 2,204 participants · Start Nov 13, 2009 · Primary completion Dec 31, 2017
Drug: Rate or Rhythm Control Therapy · For: Atrial Fibrillation; Arrhythmia
Sites: Little Rock, Arkansas; Los Angeles, California; Sacramento, California · 118 sites in all
- Antihypertensive Treatment of Acute Cerebral Hemorrhage-IIPivotal-lookingTerminated
University of MinnesotaAcademic, hospital or other
NCT01176565 · 1,000 participants · Start May 15, 2011 · Primary completion Dec 21, 2015
Drug: Intravenous nicardipine hydrochloride · For: Intracerebral Hemorrhage
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 171 sites in all
- Flecainide Safety in Patients With Coronary Artery Disease and Atrial FibrillationPivotal-lookingRecruiting
Universitaire Ziekenhuizen KU LeuvenAcademic, hospital or other
NCT07405671 · 988 participants (planned) · Start Sep 2026 · Primary completion Dec 2029
Drug: flecainide; Sotalol or Amiodarone · For: Atrial Fibrillation (AF); Coronary Artery Disease
Sites: Aalst, Belgium; Bonheiden, Belgium; Bruges, Belgium · 14 sites in all
- HALT Progression of Polycystic Kidney Disease Study APivotal-lookingCompleted
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT00283686 · 558 participants · Start Jan 2006 · Primary completion Jun 2014
Drug: Lisinopril; Telmisartan and 1 more · For: Kidney, Polycystic
Sites: Aurora, Colorado; Atlanta, Georgia; Kansas City, Kansas · 7 sites in all
Lewai Sharki Abdulaziz, MSc PhDAcademic, hospital or other
NCT04017845 · 537 participants · Start Apr 1, 2015 · Primary completion May 30, 2017
Drug: Tribenoside 400 mg + lidocaine 40 mg suppositories; Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment · For: Colorectal Neoplasms; Colorectal Cancer; Adenomatous Polyp of Colon
Sites: Baghdad, Iraq
- Diltiazem Hydrochloride Cream for Anal FissurePivotal-lookingCompleted
S.L.A. Pharma AGIndustry
NCT01217515 · 465 participants · Start Oct 2010 · Primary completion Mar 2012
Drug: Diltiazem hydrochloride 4% cream; Diltiazem hydrochloride 2% cream · For: Chronic Anal Fissure
Sites: Sevileva, Bulgaria; Sofia, Bulgaria; Veliko Tarnovo, Bulgaria · 27 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea1,394
- pain1,244
- fatigue1,212
- fall1,078
- diarrhoea949
- arthralgia940
- headache938
- dizziness930
- nausea914
- pruritus887
- drug ineffective886
- hypotension856
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 398 |
| 2005 | 412 |
| 2006 | 264 |
| 2007 | 193 |
| 2008 | 207 |
| 2009 | 201 |
| 2010 | 243 |
| 2011 | 224 |
| 2012 | 344 |
| 2013 | 306 |
| 2014 | 248 |
| 2015 | 299 |
| 2016 | 358 |
| 2017 | 353 |
| 2018 | 358 |
| 2019 | 390 |
| 2020 | 541 |
| 2021 | 895 |
| 2022 | 1,440 |
| 2023 | 1,117 |
| 2024 | 1,353 |
| 2025 | 1,308 |
| 2026 | 785 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cardizem La (Diltiazem HCl)
2024 spending
$682K
Beneficiaries
1,037
2,968 claims
Per beneficiary
$657
$3.65 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $4,591,387 |
| 2021 | $4,368,406 |
| 2022 | $4,072,302 |
| 2023 | $2,461,645 |
| 2024 | $681,664 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Anti-hypertensive therapy for preeclampsia: a network meta-analysis and systematic review.
Wang T, Jiang R, Yao Y, et al. · Hypertens Pregnancy 2024 · Systematic Review, Network Meta-Analysis
- Randomized clinical trial with topical diltiazem for post-hemorrhoidectomy wound healing.
Rodríguez-Wong U, Rodríguez-Medina U, Medina-Murillo GR · Rev Gastroenterol Mex (Engl Ed) 2019 · Randomized Controlled Trial
- Perioperative diltiazem or nitroglycerin in on-pump coronary artery bypass: A systematic review and network meta-analysis.
Hu Y, Yang X, Zhang L, et al. · PLoS One 2018 · Systematic Review, Network Meta-Analysis
- Topical analgesia following excisional haemorrhoidectomy: a systematic review and meta-analysis of randomised controlled trials.
Xia W, Park B, Otutaha BF, et al. · Int J Colorectal Dis 2020 · Meta-Analysis, Systematic Review
- A systematic review and meta-analysis of the efficacy of topical sphincterotomy treatments for anal fissure.
Jin JZ, Hardy MO, Unasa H, et al. · Int J Colorectal Dis 2022 · Meta-Analysis, Systematic Review
- Efficacy of diltiazem in the treatment of diffuse oesophageal spasm.
Drenth JP, Bos LP, Engels LG · Aliment Pharmacol Ther 1990 · Clinical Trial, Randomized Controlled Trial
Sponsor: Bausch
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.